G6PD and non-autoimmune hemolytic anemia: The field performance of the G6PD quantitative test has been previously shown in Brazil.13, 14 Consistent with previous findings, a continuous range of G6PD activity was observed with no clear breakpoints for deficient, intermediate, or normal G6PD status, underlining the need for quantitative G6PD testing to correctly identify those at risk of acute haemolytic anaemia following tafenoquine or primaquine.